nivolumab,ipilimumab
bms
['kidney cancer', 'ipilimumab', 'nivo', 'nivolumab']
esmo 2022: nivolumab + ipilimumab does not extend disease-free survival in kidney cancer #oncology
Official Twitter account of @PracticeUpdate Oncology. Includes commentaries, journal scans, conference coverage, news items & more. Part of Elsevier.